Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: Implications for HIV/AIDS treatment

Pharmacogenomics

Volumn 13, Issue 5, 2012, Pages 555-570

  Li, Jing ^a   Menard, Vincent ^b   Benish, Rebekah L ^c   Jurevic, Richard J ^d   Guillemette, Chantal ^b   Stoneking, Mark ^a   Zimmerman, Peter A ^c   Mehlotra, Rajeev K ^c  

^a MAX PLANCK INSTITUTE FOR EVOLUTIONARY ANTHROPOLOGY   (Germany)

^b UNIVERSITÉ LAVAL   (Canada)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

1000 Genomes Project; CYP2B6; efavirenz; HIV AIDS; nevirapine; Papua New Guinea; UGT2B7; zidovudine

Indexed keywords

CYTOCHROME P450 2B6; DRUG METABOLIZING ENZYME; GLUCURONOSYLTRANSFERASE 2B7;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLELE; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; CYP2B6 GENE; ETHNIC DIFFERENCE; GENE; GENE FREQUENCY; GENE STRUCTURE; GENETIC DIFFERENCE; GENETIC VARIABILITY; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HAPLOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRON; POPULATION RESEARCH; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT INDICATION; UGT2B7 GENE;

AFRICAN CONTINENTAL ANCESTRY GROUP; ANTI-HIV AGENTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENOTYPE; GLUCURONOSYLTRANSFERASE; HAPMAP PROJECT; HIV INFECTIONS; HUMAN GENOME PROJECT; HUMANS; OXIDOREDUCTASES, N-DEMETHYLATING; PAPUA NEW GUINEA; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84859236749     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.160     Document Type: Article

References (89)

1. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338(13), 853-860 (1998). (Pubitemid 28135961)
2. Conway B. The role of adherence to antiretroviral therapy in the management of HIV infection. J. Acquir. Immune Defic. Syndr. 45(Suppl. 1), S14-S18 (2007). (Pubitemid 46828215)
3. Easterbrook PJ, Phillips AN, Hill T et al. Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK. HIV Med. 9(1), 47-56 (2008).
4. Kitahata MM, Gange SJ, Abraham AG et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N. Engl. J. Med. 360(18), 1815-1826 (2009).
5. Telenti A, Zanger UM. Pharmacogenetics of anti-HIV drugs. Annu. Rev. Pharmacol. Toxicol. 48, 227-256 (2008). (Pubitemid 351738153)
6. Tozzi V. Pharmacogenetics of antiretrovirals. Antiviral Res. 85(1), 190-200 (2010).
7. Duong M, Buisson M, Peytavin G et al. Low trough plasma concentrations of nevirapine associated with virologic rebounds in HIVinfected patients who switched from protease inhibitors. Ann. Pharmacother. 39(4), 603-609 (2005). (Pubitemid 40396611)
8. Gonzalez de Requena D, Nunez M, Jimenez-Nacher I, Soriano V. Liver toxicity caused by nevirapine. AIDS 16(2), 290-291 (2002). (Pubitemid 34118577)
9. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15(1), 71-75 (2001). (Pubitemid 32055781)
10. Mentre F, Escolano S, Diquet B, Golmard JL, Mallet A. Clinical pharmacokinetics of zidovudine: inter and intraindividual variability and relationship to long term efficacy and toxicity. Eur. J. Clin. Pharmacol. 45(5), 397-407 (1993). (Pubitemid 23361937)
11. Sasomsin P, Mentre F, Diquet B, Simon F, Brun-Vezinet F. Relationship between exposure to zidovudine and decrease of P24 antigenemia in HIV-infected patients in monotherapy. Fundam. Clin. Pharmacol. 16(5), 347-352 (2002). (Pubitemid 35356944)
12. Stahle L, Moberg L, Svensson JO, Sonnerborg A. Efavirenz plasma concentrations in HIVinfected patients: inter- and intraindividual variability and clinical effects. Ther. Drug Monit. 26(3), 267-270 (2004). (Pubitemid 38703012)
13. Dahri K, Ensom MH. Efavirenz and nevirapine in HIV-1 infection: is there a role for clinical pharmacokinetic monitoring? Clin. Pharmacokinet. 46(2), 109-132 (2007). (Pubitemid 46193057)
14. Escolano S, Mentre F, Golmard JL, Diquet B, Mallet A. Plasma concentrations of zidovudine. N. Engl. J. Med. 326(23), 1571 (1992).
15. Erickson DA, Mather G, Trager WF, Levy RH, Keirns JJ. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab. Dispos. 27(12), 1488-1495 (1999).
16. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J. Pharmacol. Exp. Ther. 306(1), 287-300 (2003). (Pubitemid 36734384)
17. Zanger UM, Klein K, Saussele T, Blievernicht J, Hofmann MH, Schwab M. Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics 8(7), 743-759 (2007). (Pubitemid 47288975)
18. Watanabe T, Sakuyama K, Sasaki T et al. Functional characterization of 26 CYP2B6 allelic variants (CYP2B6.2-CYP2B6.28, except CYP2B6.22). Pharmacogenet. Genomics 20(7), 459-462 (2010).
19. Zhang H, Sridar C, Kenaan C, Amunugama H, Ballou DP, Hollenberg PF. Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional P450-reductase complex. J. Pharmacol. Exp. Ther. 338(3), 803-809 (2011).
20. Desta Z, Saussele T, Ward B et al. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics 8(6), 547-558 (2007). (Pubitemid 46947859)
21. Hofmann MH, Blievernicht JK, Klein K et al. Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. J. Pharmacol. Exp. Ther. 325(1), 284-292 (2008). (Pubitemid 351439175)
22. Cabrera SE, Santos D, Valverde MP et al. Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients. Antimicrob. Agents Chemother. 53(7), 2791-2798 (2009).
23. Haas DW, Gebretsadik T, Mayo G et al. Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African Americans. J. Infect. Dis. 199(6), 872-880 (2009).
24. Mahungu T, Smith C, Turner F et al. Cytochrome P450 2B6 516G>T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. HIV Med. 10(5), 310-317 (2009).
25. Motsinger AA, Ritchie MD, Shafer RW et al. Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study. Pharmacogenet. Genomics 16(11), 837-845 (2006). (Pubitemid 44632298)
26. Ribaudo HJ, Liu H, Schwab M et al. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. J. Infect. Dis. 202(5), 717-722 (2010).
27. Rotger M, Tegude H, Colombo S et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin. Pharmacol. Ther. 81(4), 557-566 (2007). (Pubitemid 46454205)
28. Schipani A, Wyen C, Mahungu T et al. Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. J. Antimicrob. Chemother. 66(6), 1332-1339 (2011).
29. Wyen C, Hendra H, Vogel M et al. Impact of CYP2B6 983T>C polymorphism on nonnucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J. Antimicrob. Chemother. 61(4), 914-918 (2008). (Pubitemid 351436194)
30. Ciccacci C, Borgiani P, Ceffa S et al. Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique. Pharmacogenomics 11(1), 23-31 (2010).
31. Mehlotra RK, Cheruvu VK, Zikursh MJB et al. Chemokine (C-C motif ) receptor 5 -2459 genotype in patients receiving highly active antiretroviral therapy: race-specific influence on virologic success. J. Infect. Dis. 204 (2), 291-298 (2011).
32. Carr DF, la Porte CJ, Pirmohamed M, Owen A, Cortes CP. Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort. J. Antimicrob. Chemother. 65(9), 1889-1893 (2010).
33. Chen J, Sun J, Ma Q et al. CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients. Ther. Drug Monit. 32 (5), 573-578 (2010).
34. Gatanaga H, Hayashida T, Tsuchiya K et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin. Infect. Dis. 45(9), 1230-1237 (2007). (Pubitemid 47580326)
35. Leger P, Dillingham R, Beauharnais CA et al. CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti. J. Infect. Dis. 200(6), 955-964 (2009).
36. Lindfelt T, O'Brien J, Song JC, Patel R, Winslow DL. Efavirenz plasma concentrations and cytochrome 2B6 polymorphisms. Ann. Pharmacother. 44(10), 1572-1578 (2010).
37. Puthanakit T, Tanpaiboon P, Aurpibul L, Cressey TR, Sirisanthana V. Plasma efavirenz concentrations and the association with CYP2B6-516G>T polymorphism in HIVinfected Thai children. Antivir. Ther. 14(3), 315-320 (2009).
38. Ramachandran G, Ramesh K, Hemanth Kumar AK et al. Association of high T allele frequency of CYP2B6 G516T polymorphism among ethnic south Indian HIV-infected patients with elevated plasma efavirenz and nevirapine. J. Antimicrob. Chemother. 63(4), 841-843 (2009).
39. To KW, Liu ST, Cheung SW, Chan DP, Chan RC, Lee SS. Pharmacokinetics of plasma efavirenz and CYP2B6 polymorphism in southern Chinese. Ther. Drug Monit. 31(4), 527-530 (2009).
40. Hasse B, Gunthard HF, Bleiber G, Krause M. Efavirenz intoxication due to slow hepatic metabolism. Clin. Infect. Dis. 40(3), e22-e23 (2005).
41. Barbier O, Turgeon D, Girard C et al. 3'-azido-3'-deoxythimidine (AZT) is glucuronidated by human UDPglucuronosyltransferase 2B7 (UGT2B7). Drug Metab. Dispos. 28(5), 497-502 (2000). (Pubitemid 30238507)
42. Belanger AS, Caron P, Harvey M, Zimmerman PA, Mehlotra RK, Guillemette C. Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab. Dispos. 37(9), 1793-1796 (2009).
43. Guillemette C. Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J. 3(3), 136-158 (2003). (Pubitemid 36850156)
44. Innocenti F, Liu W, Fackenthal D et al. Single nucleotide polymorphism discovery and functional assessment of variation in the UDP- glucuronosyltransferase 2B7 gene. Pharmacogenet. Genomics 18(8), 683-697 (2008).
45. Mackenzie PI, Gregory PA, Lewinsky RH et al. Polymorphic variations in the expression of the chemical detoxifying UDP glucuronosyltransferases. Toxicol. Appl. Pharmacol. 207(2 Suppl.), 77-83 (2005).
46. Shipkova M, Wieland E. Glucuronidation in therapeutic drug monitoring. Clin. Chim. Acta. 358(1-2), 2-23 (2005). (Pubitemid 40966628)
47. Kwara A, Lartey M, Sagoe KW, Kenu E, Court MH. CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIVinfected patients. AIDS 23(16), 2101-2106 (2009).
48. Kwara A, Lartey M, Boamah I et al. Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIVcoinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J. Clin. Pharmacol. 49(9), 1079-1090 (2009).
49. Elens L, Vandercam B, Yombi JC, Lison D, Wallemacq P, Haufroid V. Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1- infected patients. Pharmacogenomics 11(9), 1223-1234 (2010).
50. Arenaz I, Vicente J, Fanlo A et al. Haplotype structure and allele frequencies of CYP2B6 in Spaniards and Central Americans. Fundam. Clin. Pharmacol. 24(2), 247-253 (2010).
51. Davaalkham J, Hayashida T, Tsuchiya K, Gatanaga H, Nyamkhuu D, Oka S. Allele and genotype frequencies of cytochrome P450 2B6 gene in a Mongolian population. Drug Metab. Dispos. 37(10), 1991-1993 (2009).
52. Klein K, Lang T, Saussele T et al. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet. Genomics 15(12), 861-873 (2005). (Pubitemid 41666768)
53. Mehlotra RK, Ziats MN, Bockarie MJ, Zimmerman PA. Prevalence of CYP2B6 alleles in malaria-endemic populations of west Africa and Papua New Guinea. Eur. J. Clin. Pharmacol. 62(4), 267-275 (2006).
54. Xu BY, Guo LP, Lee SS et al. Genetic variability of CYP2B6 polymorphisms in four southern Chinese populations. World J. Gastroenterol. 13(14), 2100-2103 (2007).
55. Holthe M, Rakvag TN, Klepstad P et al. Sequence variations in the UDPglucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Pharmacogenomics J. 3(1), 17-26 (2003). (Pubitemid 36432463)
56. Saeki M, Saito Y, Jinno H et al. Single nucleotide polymorphisms and haplotype frequencies of UGT2B4 and UGT2B7 in a Japanese population. Drug Metab. Dispos. 32(9), 1048-1054 (2004). (Pubitemid 39096067)
57. Saito K, Moriya H, Sawaguchi T et al. Haplotype analysis of UDPglucuronocyltransferase 2B7 gene (UGT2B7) polymorphisms in healthy Japanese subjects. Clin. Biochem. 39(3), 303-308 (2006).
58. Mehlotra RK, Bockarie MJ, Zimmerman PA. CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment. Br. J. Clin. Pharmacol. 64(3), 391-395 (2007). (Pubitemid 47283857)
59. Mehlotra RK, Bockarie MJ, Zimmerman PA. Prevalence of UGT1A9 and UGT2B7 nonsynonymous single nucleotide polymorphisms in west African, Papua New Guinean, and north American populations. Eur. J. Clin. Pharmacol. 63(1), 1-8 (2007). (Pubitemid 46025467)
60. -1000 Genomes Project Consortium. A map of human genome variation from populationscale sequencing. Nature 467(7319), 1061-1073 (2010).
61. Zimmerman PA, Dadzie KY, De Sole G, Remme J, Alley ES, Unnasch TR: Onchocerca volvulus DNA probe classification correlates with epidemiologic patterns of blindness. J. Infect. Dis. 165(5), 964-968 (1992).
62. Zimmerman PA, Woolley I, Masinde GL et al. Emergence of FY*A(null) in a Plasmodium vivax-endemic region of Papua New Guinea. Proc. Natl Acad. Sci. USA 96(24), 13973-13977 (1999).
63. Burchard EG, Borrell LN, Choudhry S et al. Latino populations: a unique opportunity for the study of race, genetics, and social environment in epidemiological research. Am. J. Public Health 95, 2161-2168 (2005) (Pubitemid 41740246)
64. Lamba V, Lamba J, Yasuda K et al. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J. Pharmacol. Exp. Ther. 307(3), 906-922 (2003). (Pubitemid 37494207)
65. Solus JF, Arietta BJ, Harris JR et al. Genetic variation in eleven Phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 5(7), 895-931 (2004). (Pubitemid 39386756)
66. Ingman M, Gyllensten U. A recent genetic link between Sami and the Volga-Ural region of Russia. Eur. J. Hum. Genet. 15(1), 115-120 (2007). (Pubitemid 44921675)
67. Kittles RA, Perola M, Peltonen L et al. Dual origins of Finns revealed by Y chromosome haplotype variation. Am. J. Hum. Genet. 62(5), 1171-1179 (1998). (Pubitemid 28199019)
68. Salmela E, Lappalainen T, Fransson I et al. Genome-wide analysis of single nucleotide polymorphisms uncovers population structure in northern Europe. PLoS ONE 3(10), e3519 (2008).
69. Altshuler DM, Gibbs RA, Peltonen L et al. Integrating common and rare genetic variation in diverse human populations. Nature 467(7311), 52-58 (2010).
70. Bhasker CR, McKinnon W, Stone A et al. Genetic polymorphism of UDPglucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 10(8), 679-685 (2000).
71. Hwang MS, Lee SJ, Jeong HE, Lee S, Yoo MA, Shin JG. Genetic variations in UDPglucuronosyltransferase 2B7 gene (UGT2B7) in a Korean population. Drug Metab. Pharmacokinet. 25(4), 398-402 (2010).
72. Ferlin A, Ganz F, Pengo M, Selice R, Frigo AC, Foresta C. Association of testicular germ cell tumor with polymorphisms in estrogen receptor and steroid metabolism genes. Endocr. Relat. Cancer 17(1), 17-25 (2010).
73. Wang J, Sonnerborg A, Rane A et al. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet. Genomics 16(3), 191-198 (2006).
74. Bonnen PE, Wang PJ, Kimmel M, Chakraborty R, Nelson DL. Haplotype and linkage disequilibrium architecture for human cancer-associated genes. Genome Res. 12(12), 1846-1853 (2002). (Pubitemid 35469933)
75. Li J, Zhang L, Zhou H, Stoneking M, Tang K. Global patterns of genetic diversity and signals of natural selection for human ADME genes. Hum. Mol. Genet. 20 (3), 528-540 (2011).
76. Myles S, Tang K, Somel M, Green RE, Kelso J, Stoneking M. Identification and analysis of genomic regions with large betweenpopulation differentiation in humans. Ann. Hum. Genet. 72(Pt 1), 99-110 (2008).
77. Rakhmanina NY, van den Anker JN. Efavirenz in the therapy of HIV infection. Expert Opin. Drug Metab. Toxicol. 6(1), 95-103 (2010).
78. Rotger M, Telenti A. Optimizing efavirenz treatment: CYP2B6 genotyping or therapeutic drug monitoring? Eur. J. Clin. Pharmacol. 64(4), 335-336 (2008).
79. Yuan J, Guo S, Hall D et al. Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. AIDS 25(10), 1271-1280 (2011).
80. Duguay Y, Baar C, Skorpen F, Guillemette C. A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity. Clin. Pharmacol. Ther. 75(3), 223-233 (2004). (Pubitemid 38314872)
81. Court MH, Krishnaswamy S, Hao Q et al. Evaluation of 3′-azido- 3′-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab. Dispos. 31(9), 1125-1133 (2003). (Pubitemid 37048284)
82. Takekuma Y, Takenaka T, Yamazaki K, Ueno K, Sugawara M. Stereoselective metabolism of racemic carvedilol by UGT1A1 and UGT2B7, and effects of mutation of these enzymes on glucuronidation activity. Biol. Pharm .Bull. 30(11), 2146-2153 (2007). (Pubitemid 350097059)
83. Honda M, Toyoda W, Shimizu T et al. UGT2B7*3 did not affect the pharmacokinetics of R- and S-carvedilol in healthy Japanese. Drug Metab. Pharmacokinet. 22(5), 382-386 (2007).
84. Takekuma Y, Takenaka T, Kiyokawa M et al. Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis. Biol. Pharm .Bull. 30(3), 537-542 (2007). (Pubitemid 46355942)
85. di Iulio J, Fayet A, Arab-Alameddine M et al. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet. Genomics 19(4), 300-309 (2009).
86. Grady BJ, Torstenson ES, McLaren PJ et al. Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenzcontaining treatment regimens in ART-naive ACTG clinical trials participants. Pac. Symp. Biocomput. 2011, 253-264
87. Wyen C, Hendra H, Siccardi M et al. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. J. Antimicrob. Chemother. (2011).
88. Ishii Y, Takeda S, Yamada H. Modulation of UDP-glucuronosyltransferase activity by protein-protein association. Drug Metab. Rev. 42(1), 145-158 (2010).
89. Menard V, Eap O, Roberge J, Harvey M, Levesque E, Guillemette C. Transcriptional diversity at the UGT2B7 locus is dictated by extensive pre-mRNA splicing mechanisms that give rise to multiple mRNA splice variants. Pharmacogenet. Genomics 21(10), 631-641 (2011).